Development of a New Service in the Metabolome Analysis Business

「By service, the biomanufacturing support service received orders at a strong pace after its July launch and achieved sales of ¥127.226 million, exceeding the annual sales target. The functionality-material development support service also increased sales to ¥363.885 million, up 16.6% from the previous consolidated fiscal year, driven by strong orders for offerings such as the health-claims measurement package.」

「We are developing proprietary technology that enables comprehensive analysis of medium-sized molecules, whose molecular weights are between those of low-molecular-weight compounds, such as metabolites, and high-molecular-weight compounds, such as proteins, and will offer it as a medium-molecule metabolomics service.」

「In R&D, the company advanced activities focused mainly on developing new highly sensitive comprehensive analysis services and additional functionality-material development support services.」

「In addition to promoting research and development focused on developing new services for highly sensitive comprehensive analysis and expanding the functional materials development support service, we promoted research and development aimed at commercializing mental health biomarkers.」

「In addition to promoting research and development focused on developing new services for highly sensitive comprehensive analysis and expanding the functional materials development support service, we promoted research and development aimed at commercializing mental health biomarkers.」

「By advancing these initiatives, we aim to achieve sustainable revenue and profit growth, as before.」

「In this business segment, sales of highly sensitive comprehensive metabolite analysis services in Japan and overseas, as well as other contract omics services introduced from partners to expand the service menu, remained firm, resulting in higher sales, mainly in the academic and pharmaceutical sectors. Sales of contract metabolite analysis services in Europe and the United States also increased substantially.」

「In this business segment, sales of highly sensitive comprehensive metabolite analysis services in Japan and overseas, as well as other contract omics services introduced from partners to expand the service menu, remained firm, resulting in higher sales, mainly in the academic sector.」

「Lipidome analysis, for which the company entered into a business alliance in the fiscal year ended June 2020, performed well as the company focused on expanding its service menu and sales, particularly by meeting demand from pharmaceutical companies.」

「Orders from academia and pharmaceutical companies increased substantially, particularly as a result of expanded sales of highly sensitive comprehensive analysis services and lipid analysis services, leading to a significant increase in domestic sales.」

「By enhancing the added value of services through the development of new contract analysis offerings, implementing marketing initiatives and strengthening sales activities to expand the customer base, we aim to increase sales mainly in the food, chemicals and pharmaceutical sectors」

「By enhancing the added value of services through the development of new contract analysis offerings, implementing marketing initiatives and strengthening sales activities to expand the customer base, we aim to increase sales mainly in the food, chemicals and pharmaceutical sectors」

「We focused on securing orders for the new services launched in April and October 2018.」

「In this business segment, the Group continued to conduct active promotional activities, as in the previous fiscal year, worked to expand orders for large projects in the pharmaceutical, food and other fields, and focused on securing orders for new services launched in April and October 2018.」

「In this business segment, the Group continued to conduct active promotional activities, as in the previous fiscal year, worked to expand orders for large projects in the pharmaceutical, food and other fields, and focused on securing orders for new services launched in April and October 2018.」

「In this business segment, the Group continued to conduct active promotional activities, as in the previous fiscal year, worked to expand orders for large projects in the pharmaceutical, food and other fields, and focused on securing orders for a new service launched in April 2018.」

「We focused on securing orders for the new service launched in April 2018.」

「In this business segment, the Group continued to conduct active promotional activities, as in the previous fiscal year, worked to expand orders for large projects in the chemical, pharmaceutical and other fields, and promoted research and development activities aimed at expanding the lineup of analytical services.」

「In this business segment, the Group continued to conduct active promotional activities, as in the previous fiscal year, worked to expand orders for large projects in the chemical, pharmaceutical and other fields, and strengthened its organisational structure and equipment to develop new services.」

「In this business segment, the Group continued to conduct active promotional activities, as in the previous fiscal year, worked to expand orders for large projects in the pharmaceutical and other fields, and promoted the development of new services.」

「We will work to enhance the added value of our services through the development of new measurement and analysis plans, among other initiatives.」

「In addition, the company worked to improve the productivity of analysis and testing operations and other activities after receiving samples, and to develop new services.」